Yasmin Hisham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yasmin Hisham has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Jaewoo Hong
Department of Physiology, School of Medicine, Daegu Catholic University, Daegu 42472, Republic of Korea
2 shared publications - Soohyun Kim
Konkuk University
2 shared publications - Alistair R. R. Forrest
Harry Perkins Institute of Medical Research, QEII Medical Centre and Centre for Medical Research, The University of Western Australia, Nedlands, Perth, WA 6009, Australia
1 shared publication - Chang-Seon Song
Avian Disease Laboratory, College of Veterinary Medicine, Konkuk University, Seoul 05029, Republic of Korea
1 shared publication - Ho-Young Park
Food Functionality Research Division, Korea Food Research Institute, Wanju-gun, Republic of Korea
1 shared publication - Hyun Mu Shin
Department of Biomedical Sciences, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 31 October 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (D1) , D546-D554
connectomeDB2025: a rigorously curated, multi-species resource of experimentally supported ligand–receptor interactions
Inferring cell–cell communication networks is now a cornerstone of single-cell RNA-seq and spatial transcriptomics data analysis, relying critically on reference catalogues of experimentally supported ligand–receptor interactions. Here, we present the updated, rigorously curated connectomeDB, an open-access database of peptide-based ligand–receptor pairs comprising 3579 vertebrate interactions supported by primary experimental evidence from 2803 research articles. By critically reviewing all putative ligand–receptor pairs from connectomeDB2020, CellChatDB v2, CellPhoneDB v5, CellTalkDB, ICELLNET v2, and LIANA+, we first removed over 2900 misclassified or unsupported interactions lacking primary-literature evidence. We then expanded the resulting verified dataset through AI-assisted literature mining and manual curation, adding 827 pairs and 718 supporting articles absent from other databases, including 264 pairs first described since 2020. connectomeDB2025 contains 5429 evidence links (“triplets”), each connecting a ligand–receptor pair to a specific publication, collectively providing at least one source of primary experimental evidence for each interaction. Notably, 2359 of these triplets are exclusive to connectomeDB2025, making it the most robustly supported ligand–receptor database with primary experimental evidence. The online resource (https://connectomedb.org) provides searchable, downloadable ligand–receptor lists and detailed pair summaries, enabling accurate cell–cell communication analysis across human, mouse, and 12 other vertebrate species.
- 31 October 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (D1) , D546-D554
Open AccessconnectomeDB2025: a rigorously curated, multi-species resource of experimentally supported ligand–receptor interactions
Inferring cell–cell communication networks is now a cornerstone of single-cell RNA-seq and spatial transcriptomics data analysis, relying critically on reference catalogues of experimentally supported ligand–receptor interactions. Here, we present the updated, rigorously curated connectomeDB, an open-access database of peptide-based ligand–receptor pairs comprising 3579 vertebrate interactions supported by primary experimental evidence from 2803 research articles. By critically reviewing all putative ligand–receptor pairs from connectomeDB2020, CellChatDB v2, CellPhoneDB v5, CellTalkDB, ICELLNET v2, and LIANA+, we first removed over 2900 misclassified or unsupported interactions lacking primary-literature evidence. We then expanded the resulting verified dataset through AI-assisted literature mining and manual curation, adding 827 pairs and 718 supporting articles absent from other databases, including 264 pairs first described since 2020. connectomeDB2025 contains 5429 evidence links (“triplets”), each connecting a ligand–receptor pair to a specific publication, collectively providing at least one source of primary experimental evidence for each interaction. Notably, 2359 of these triplets are exclusive to connectomeDB2025, making it the most robustly supported ligand–receptor database with primary experimental evidence. The online resource (https://connectomedb.org) provides searchable, downloadable ligand–receptor lists and detailed pair summaries, enabling accurate cell–cell communication analysis across human, mouse, and 12 other vertebrate species.
- Open Access
- 30 September 2025
- Published by Scilight Press Pty Ltd in Journal of Inflammatory and Infectious Medicine
- Vol. 1 (3) , 3
Long Non-Coding RNAs in Viral Immunity: From Regulatory Mechanisms to Therapeutic Potential
Long non-coding RNAs (lncRNAs) are a class of regulatory RNAs that do not encode proteins but play essential roles in controlling gene expression at multiple levels, including chromatin modification, transcription, and RNA stability. LncRNAs have emerged as important regulators of antiviral immunity. These molecules function in both cis and trans to modulate chromatin states, guide transcription factors, scaffold signaling complexes, or act as decoys for regulatory proteins and RNAs. During viral infection, host lncRNAs are dynamically expressed and can either enhance antiviral responses or be hijacked by viruses to suppress immunity, promote replication, or facilitate latency. Virus-encoded lncRNAs also manipulate host gene expression to their advantage. Recent research has uncovered specific lncRNAs involved in regulating interferon signaling, cytokine production, antigen presentation, and immune cell differentiation. Concurrently, advances in computational biology have enabled the discovery and characterization of lncRNAs through methods such as RNA-seq analysis, transcript assembly, coding potential prediction, co-expression network analysis, and interaction modeling with proteins and RNAs. Functional inference is further supported by enrichment analyses and studies of conservation and localization. This mini review summarizes the current understanding of host and viral lncRNAs in antiviral defense and pathogenesis. It also highlights the translational potential of lncRNAs as biomarkers and therapeutic targets, discussing emerging strategies including CRISPR-based modulation, synthetic RNA therapeutics, and innovative delivery methods. Together, these findings underscore the critical role of lncRNAs in viral immunity and their promise in guiding novel approaches for diagnosing and treating viral infections.
- 30 September 2025
- Published by Scilight Press Pty Ltd in Journal of Inflammatory and Infectious Medicine
- Vol. 1 (3) , 3
Open AccessLong Non-Coding RNAs in Viral Immunity: From Regulatory Mechanisms to Therapeutic Potential
Long non-coding RNAs (lncRNAs) are a class of regulatory RNAs that do not encode proteins but play essential roles in controlling gene expression at multiple levels, including chromatin modification, transcription, and RNA stability. LncRNAs have emerged as important regulators of antiviral immunity. These molecules function in both cis and trans to modulate chromatin states, guide transcription factors, scaffold signaling complexes, or act as decoys for regulatory proteins and RNAs. During viral infection, host lncRNAs are dynamically expressed and can either enhance antiviral responses or be hijacked by viruses to suppress immunity, promote replication, or facilitate latency. Virus-encoded lncRNAs also manipulate host gene expression to their advantage. Recent research has uncovered specific lncRNAs involved in regulating interferon signaling, cytokine production, antigen presentation, and immune cell differentiation. Concurrently, advances in computational biology have enabled the discovery and characterization of lncRNAs through methods such as RNA-seq analysis, transcript assembly, coding potential prediction, co-expression network analysis, and interaction modeling with proteins and RNAs. Functional inference is further supported by enrichment analyses and studies of conservation and localization. This mini review summarizes the current understanding of host and viral lncRNAs in antiviral defense and pathogenesis. It also highlights the translational potential of lncRNAs as biomarkers and therapeutic targets, discussing emerging strategies including CRISPR-based modulation, synthetic RNA therapeutics, and innovative delivery methods. Together, these findings underscore the critical role of lncRNAs in viral immunity and their promise in guiding novel approaches for diagnosing and treating viral infections.
- Open Access
- 23 June 2025
- Published by Scilight Press Pty Ltd in Journal of Inflammatory and Infectious Medicine
- Vol. 1 (2) , 6
Identification of a Novel Human Peroxiredoxin-6 (PRDX6) Promoter Region Sequence
Peroxiredoxin-6 (PRDX6) is an oxidative stress response protein with multiple roles under reactive oxygen species (ROS)-mediated conditions. The multifunctional cytoprotective role of the protein PRDX6 is to maintain cellular homeostasis and membrane integrity through intracellular ROS and phospholipid turnover. The PRDX6 promoter region has been reported in several biological regulations because of its key binding sites. However, the human PRDX6 promoter sequence is not yet fully understood. In this study, we discovered and characterized the proximal promoter sequence of human PRDX6. Interestingly, the identified human PRDX6 promoter was about 1 kb shorter than the one reported in the database. Further studies with the new human PRDX6 promoter analysis will help to understand intracellular ROS and phospholipid turnover to maintain cellular homeostasis. This report provides the human PRDX6 proximal promoter sequence.
- 23 June 2025
- Published by Scilight Press Pty Ltd in Journal of Inflammatory and Infectious Medicine
- Vol. 1 (2) , 6
Open AccessIdentification of a Novel Human Peroxiredoxin-6 (PRDX6) Promoter Region Sequence
Peroxiredoxin-6 (PRDX6) is an oxidative stress response protein with multiple roles under reactive oxygen species (ROS)-mediated conditions. The multifunctional cytoprotective role of the protein PRDX6 is to maintain cellular homeostasis and membrane integrity through intracellular ROS and phospholipid turnover. The PRDX6 promoter region has been reported in several biological regulations because of its key binding sites. However, the human PRDX6 promoter sequence is not yet fully understood. In this study, we discovered and characterized the proximal promoter sequence of human PRDX6. Interestingly, the identified human PRDX6 promoter was about 1 kb shorter than the one reported in the database. Further studies with the new human PRDX6 promoter analysis will help to understand intracellular ROS and phospholipid turnover to maintain cellular homeostasis. This report provides the human PRDX6 proximal promoter sequence.
- Open Access
- 12 June 2025
- Published by Scilight Press Pty Ltd in Journal of Inflammatory and Infectious Medicine
- Vol. 1 (2) , 3
IL-32γ plays a neuroprotective role after acute stroke in MCAO mouse model
Stroke is believed to be the most common cause of permanent disability and is regarded as the second major cause of death. Within minutes of onset, cerebral ischemia triggers a cascade of pathophysiological events that ultimately result in irreversible tissue damage. Post-ischemic inflammation plays a critical role in cerebral ischemia-reperfusion injury, characterized by the elevated release of cytokines and chemokines. Interleukin (IL)-32 is known to induce several cytokines, particularly pro-inflammatory ones such as IL-6, tumor necrosis factor (TNF)α, and IL-1β. Targeting inflammatory pathways are of great interest in stroke research. In this study, we investigated the role of IL-32γ in a middle cerebral artery occlusion (MCAO) model using transgenic (TG) mice expressing human IL-32γ. Compared to wild-type (WT) mice, IL-32γ TG mice exhibited a significantly reduced infarct volume after MCAO. Accompanying the decreased brain tissue damage, the levels of pro-inflammatory cytokines IL-6, TNFα, and IL-1β were markedly lower in IL-32γ TG mice than in WT controls. These findings suggest that IL-32γ modulates the inflammatory response in ischemic brain injury. Specifically, IL-32γ reduced the expression of pro-inflammatory cytokines and the number of apoptotic cells following ischemic insult. In conclusion, our results demonstrate that IL-32γ regulates the neuroinflammatory response in brain injury and may serve as a potential neuroprotective therapeutic target.
- 12 June 2025
- Published by Scilight Press Pty Ltd in Journal of Inflammatory and Infectious Medicine
- Vol. 1 (2) , 3
Open AccessIL-32γ plays a neuroprotective role after acute stroke in MCAO mouse model
Stroke is believed to be the most common cause of permanent disability and is regarded as the second major cause of death. Within minutes of onset, cerebral ischemia triggers a cascade of pathophysiological events that ultimately result in irreversible tissue damage. Post-ischemic inflammation plays a critical role in cerebral ischemia-reperfusion injury, characterized by the elevated release of cytokines and chemokines. Interleukin (IL)-32 is known to induce several cytokines, particularly pro-inflammatory ones such as IL-6, tumor necrosis factor (TNF)α, and IL-1β. Targeting inflammatory pathways are of great interest in stroke research. In this study, we investigated the role of IL-32γ in a middle cerebral artery occlusion (MCAO) model using transgenic (TG) mice expressing human IL-32γ. Compared to wild-type (WT) mice, IL-32γ TG mice exhibited a significantly reduced infarct volume after MCAO. Accompanying the decreased brain tissue damage, the levels of pro-inflammatory cytokines IL-6, TNFα, and IL-1β were markedly lower in IL-32γ TG mice than in WT controls. These findings suggest that IL-32γ modulates the inflammatory response in ischemic brain injury. Specifically, IL-32γ reduced the expression of pro-inflammatory cytokines and the number of apoptotic cells following ischemic insult. In conclusion, our results demonstrate that IL-32γ regulates the neuroinflammatory response in brain injury and may serve as a potential neuroprotective therapeutic target.
- Open Access
- 20 July 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (7) , 1750
Interleukin-18 Binding Protein in Immune Regulation and Autoimmune Diseases
Natural soluble antagonist and decoy receptor on the surface of the cell membrane are evolving as crucial immune system regulators as these molecules are capable of recognizing, binding, and neutralizing (so-called inhibitors) their targeted ligands. Eventually, these soluble antagonists and decoy receptors terminate signaling by prohibiting ligands from connecting to their receptors on the surface of cell membrane. Interleukin-18 binding protein (IL-18BP) participates in regulating both Th1 and Th2 cytokines. IL-18BP is a soluble neutralizing protein belonging to the immunoglobulin (Ig) superfamily as it harbors a single Ig domain. The Ig domain is essential for its binding to the IL-18 ligand and holds partial homology to the IL-1 receptor 2 (IL-1R2) known as a decoy receptor of IL-1α and IL-1β. IL-18BP was defined as a unique soluble IL-18BP that is distinct from IL-18Rα and IL-18Rβ chain. IL-18BP is encoded by a separated gene, contains 8 exons, and is located at chr.11 q13.4 within the human genome. In this review, we address the difference in the biological activity of IL-18BP isoforms, in the immunity balancing Th1 and Th2 immune response, its critical role in autoimmune diseases, as well as current clinical trials of recombinant IL-18BP (rIL-18BP) or equivalent.
- 20 July 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (7) , 1750
Open AccessInterleukin-18 Binding Protein in Immune Regulation and Autoimmune Diseases
Natural soluble antagonist and decoy receptor on the surface of the cell membrane are evolving as crucial immune system regulators as these molecules are capable of recognizing, binding, and neutralizing (so-called inhibitors) their targeted ligands. Eventually, these soluble antagonists and decoy receptors terminate signaling by prohibiting ligands from connecting to their receptors on the surface of cell membrane. Interleukin-18 binding protein (IL-18BP) participates in regulating both Th1 and Th2 cytokines. IL-18BP is a soluble neutralizing protein belonging to the immunoglobulin (Ig) superfamily as it harbors a single Ig domain. The Ig domain is essential for its binding to the IL-18 ligand and holds partial homology to the IL-1 receptor 2 (IL-1R2) known as a decoy receptor of IL-1α and IL-1β. IL-18BP was defined as a unique soluble IL-18BP that is distinct from IL-18Rα and IL-18Rβ chain. IL-18BP is encoded by a separated gene, contains 8 exons, and is located at chr.11 q13.4 within the human genome. In this review, we address the difference in the biological activity of IL-18BP isoforms, in the immunity balancing Th1 and Th2 immune response, its critical role in autoimmune diseases, as well as current clinical trials of recombinant IL-18BP (rIL-18BP) or equivalent.
- Open Access
- 1 January 2021
- Published by XMLink in Immune Network
- Vol. 21 (5)
SARS-CoV-2 Delta (B.1.617.2) Variant: A Unique T478K Mutation in Receptor Binding Motif (RBM) of Spike Gene
Jhun H, et al. Immune Netw. 2021 Oct;21(5):e32. https://doi.org/10.4110/in.2021.21.e32
- 1 January 2021
- Published by XMLink in Immune Network
- Vol. 21 (5)
Open AccessSARS-CoV-2 Delta (B.1.617.2) Variant: A Unique T478K Mutation in Receptor Binding Motif (RBM) of Spike Gene
Jhun H, et al. Immune Netw. 2021 Oct;21(5):e32. https://doi.org/10.4110/in.2021.21.e32